Navigation Links
University Hospitals Case Medical Center testing gene therapy for Alzheimer's disease
Date:1/7/2010

University Hospitals Case Medical Center is one of 12 sites conducting the first Phase 2 clinical trial of a gene therapy for Alzheimer's disease (AD). The study uses a viral-based gene transfer system called CERE-110, which is designed to deliver nerve growth factor (NGF) into the brain. University Hospitals (UH) is the only site in the Midwest for the study. The study is sponsored by a contract to Case Western Reserve University from the Alzheimer's Disease Cooperative Study (ADCS) through a grant from the National Institute on Aging in association with Ceregene, Inc., which developed and will provide the active agent CERE-110.

NGF is a naturally occurring protein that may prevent nerve cells in the brain from dying and may help these cells function better. During the study, CERE-110 will be injected by a neurosurgeon into the nucleus basalis of Meynert, an area of the brain where nerve cells die in patients with AD.

"A small study in humans showed that CERE-110 was generally safe and well-tolerated," said Alan J. Lerner, M.D., principal investigator of the Cleveland site, director of the UH Neurological Institute Memory and Cognition Center, and a professor of neurology at the Case Western Reserve University School of Medicine.

The Phase 2 study will evaluate whether the therapy is safe for a larger group of patients and whether it helps the symptoms of AD. In total, 50 patients will be enrolled throughout the United States and UH aims to enroll at least five patients in this study.

"Should the clinical development of this therapy be successful, CERE-110 could offer the possibility of delaying the course of Alzheimer's disease, a real improvement over existing therapies," said Dr. Lerner. "This would not be a cure for AD, but a way of slowing it down."

Participants in the Phase 2 study will be randomly placed into one of two treatment groups, with half of the subjects receiving CERE-110 and the other half receiving placebo surgery. At the completion of the trial, subjects in the placebo arm may have the opportunity to receive the active treatment if the product seems safe and effective.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. A study by the MUHC and McGill University opens a new door to understanding cancer
2. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
3. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
4. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
5. Binghamton University researchers investigate evolving malaria resistance
6. Antioxidant to retard wrinkles discovered by Hebrew University researcher
7. Society for General Microbiology 161st Meeting, University of Edinburgh
8. Boston University biomedical engineers find chink in bacterias armor
9. KAUST and American University in Cairo to collaborate on research and academic development
10. UNH becomes first university in nation to use landfill gas as primary energy source
11. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology: